Loading...
Efforts to deescalate the use of chemotherapy in early-stage breast cancer have been ongoing for the last decade, as molecular assays began to be used in clinical decision making. One of the most common prognostic tools in clinical practice is the 21-gene recurrence score (RS; Oncotype DX). Since it was introduced a decade ago for ER+/HER2−, node-negative breast cancer, fewer patients are receiving adjuvant chemotherapy and instead are being treated with endocrine therapy alone. Although RS results at the extremes offer clinicians clarity regarding treatment — chemo-endocrine therapy for high scores and endocrine therapy alone for low scores — intermediate RS results do not help determine the optimal adjuvant therapy.
To address this issue, …